International journal of molecular sciences

RNA-Based Treatments for Duchenne Muscular Dystrophy Using Exon Skipping, RNA Editing, and Insights from Genetically Modified Mini-Pig Models

Updated

Abstract

Essence

and are presented as complementary RNA strategies for DMD, with genome-edited microminipigs positioned as a translational testing model.

Evidence

Evidence is a narrative review of exon-skipping clinical progress, RNA-editing concepts, and DMD microminipig model features including muscle, cardiac, and lifespan readouts.

Caveat

The review does not test a new therapy, and efficient delivery to the heart and diaphragm remains a persistent translational challenge.

Simplified

Key numbers

40 years
Life Expectancy Increase
Life expectancy for DMD patients has increased from around 20 years to 40 years with glucocorticoid treatment.
1–10%
Dystrophin Restoration Levels
Dystrophin restoration levels from RNA therapies generally range from 1% to 10% of normal.
1 in 4000–5000
DMD Prevalence
DMD affects approximately 1 in 4000–5000 newborn boys worldwide each year.

Full Text

What this is

  • Duchenne muscular dystrophy (DMD) is a severe genetic disorder affecting muscle function, primarily in boys.
  • RNA-based therapies, particularly and , are emerging as promising treatment strategies.
  • Large-animal models, especially genome-edited microminipigs, are crucial for evaluating these therapies' efficacy and safety.
  • This review synthesizes current clinical advancements and highlights the translational potential of RNA-based approaches for DMD.

Essence

  • RNA-based therapies like and show promise for treating Duchenne muscular dystrophy (DMD). Genome-edited microminipigs serve as effective models for testing these therapies, bridging the gap between preclinical studies and human trials.

Key takeaways

  • aims to produce a truncated but functional dystrophin protein by excluding specific exons during mRNA processing. This approach has led to the development of several PMO-based therapies that target the most frequently mutated exons in the dystrophin gene.
  • offers a method to correct specific mutations at the RNA level, potentially restoring full-length dystrophin expression. This strategy is particularly relevant for patients with nonsense mutations.
  • The DMD-microminipig model closely resembles human DMD pathology, allowing for better assessment of therapeutic delivery and efficacy. Its lifespan and physiological similarities make it a valuable platform for long-term studies of RNA-based therapies.

Caveats

  • Current RNA-based therapies show limited efficacy, with dystrophin restoration levels generally ranging from 1% to 10% of normal. This modest restoration does not halt disease progression.
  • The reliance on repeated administration of ASOs poses a treatment burden and may affect patient quality of life. Lifelong therapy is necessary as ASOs do not integrate into the genome.
  • Inter-individual variability in therapeutic response complicates the clinical implementation of RNA-based therapies, necessitating personalized treatment strategies.

Definitions

  • exon skipping: A therapeutic strategy that induces selective exclusion of specific exons from pre-mRNA, producing a truncated but functional protein.
  • RNA editing: A technique that corrects specific RNA mutations by converting adenosine to inosine, potentially restoring protein function without altering genomic DNA.

Simplified

Funding

Competing interests

0 of 5
authors report competing interests
5 report none
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free